PolyPid Ltd. (NASDAQ:PYPD) Short Interest Update

PolyPid Ltd. (NASDAQ:PYPD) saw a large decrease in short interest during the month of November. As of November 15th, there was short interest totalling 13,000 shares, a decrease of 15.6% from the October 31st total of 15,400 shares. Currently, 0.4% of the shares of the stock are short sold. Based on an average trading volume of 7,000 shares, the short-interest ratio is presently 1.9 days.

PolyPid Stock Down 3.3 %

Shares of NASDAQ:PYPD opened at $3.34 on Friday. The business has a fifty day simple moving average of $3.47 and a 200 day simple moving average of $3.72. PolyPid has a 12-month low of $2.95 and a 12-month high of $9.20. The firm has a market cap of $16.03 million, a P/E ratio of -0.43 and a beta of 1.31. The company has a quick ratio of 1.00, a current ratio of 1.00 and a debt-to-equity ratio of 1.17.

Wall Street Analysts Forecast Growth

PYPD has been the topic of a number of research reports. HC Wainwright restated a “buy” rating and set a $14.00 price objective on shares of PolyPid in a research report on Wednesday, October 2nd. Craig Hallum initiated coverage on PolyPid in a research note on Monday, November 4th. They set a “buy” rating and a $10.00 price target on the stock.

Hedge Funds Weigh In On PolyPid

A hedge fund recently bought a new stake in PolyPid stock. Stonepine Capital Management LLC purchased a new position in PolyPid Ltd. (NASDAQ:PYPD) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 138,504 shares of the company’s stock, valued at approximately $476,000. Stonepine Capital Management LLC owned 2.89% of PolyPid as of its most recent filing with the Securities and Exchange Commission. 26.47% of the stock is currently owned by institutional investors.

PolyPid Company Profile

PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions.